COLL is positioned in the Pharmaceuticals industry. The balance sheet carries approximately $1.66 billion in total assets, with net income near $62.87 million. The company generates approximately $329.32 million in operating cash flow.
At $39.32, Collegium Pharmaceutical continues to demonstrate a 7.70% increase in today's market action after opening at $36.51. Collegium Pharmaceutical shows an estimated 9% exposure to potential financial distress, consistent with a relatively small probability. Return data over the last 90 trading days classifies Collegium Pharmaceutical as weak in terms of performance. The performance scores reflect data spanning February 6, 2026 through May 7, 2026. Learn more.
Collegium Pharmaceutical (COLL) is listed on NASDAQ Exchange in USA. COLL conducts business in the Health Care industry (Pharmaceuticals sector). The latest market cap read on Collegium Pharmaceutical is $1.14 billion, positioning the company in the mid-cap group across health care companies. The current market cap profile is reinforced by enterprise value near $1.55 billion, a workforce of about 423 people, and about 32.41 million shares outstanding. COLL has 6.03 million shares sold short (9.32 days to cover). The gap between operating margin (30.04%) and net margin (8.05%) suggests significant non-operating costs such as interest or taxes. Collegium Pharmaceutical is an operator in the health care segment where revenue is driven by core operating activity and end-market demand. COLL reported previous year's revenue of $780.57 million. Net Income was $62.87 million with profit before overhead, payroll, taxes, and interest of $693.64 million. Collegium Pharmaceutical financial stability analysisOwnership Allocation The majority of Collegium Pharmaceutical's outstanding shares are owned by institutional holders. High institutional ownership often reflects the stock's eligibility for passive index funds, which are required to hold positions proportional to index weights regardless of their own investment view. Active managers holding Collegium Pharmaceutical must also disclose positions above certain thresholds through SEC filings.
Check Collegium Ownership Details
SAMPP Small-Cap 600, NASDAQ Health Care, NASDAQ Biotechnology, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare, (View all Sectors)
Common Risk Profiles
Risk-return optimization is the central goal of equity investing. Collegium Pharmaceutical market risk premium is the additional compensation investors demand for the systematic risk of holding Collegium Pharmaceutical. Analysts apply CAPM to determine whether Collegium Pharmaceutical return adequately compensates for its market risk. This systematic view of Collegium Pharmaceutical risk premium supports disciplined portfolio construction decisions.
Collegium Pharmaceutical is scheduled to announce its earnings today. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Collegium Pharmaceutical was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Collegium Pharmaceutical employs 423 people. Headquarters are in 100 Technology Center Drive, Stoughton, MA, United States, 02072. Key reported metrics include market cap 1.14 billion, P/E 28.8. Collegium Pharmaceutical operates in SAMPP Small-Cap 600, NASDAQ Health Care, NASDAQ Biotechnology. Reported fundamentals are aligned with observed market behavior. The asset's responsiveness to economic cycles appears relatively balanced.
Methodology
Unless otherwise specified, financial data for Collegium Pharmaceutical is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Collegium (USA Stocks:COLL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: Information for Collegium Pharmaceutical is compiled from public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR. Reporting latency may occur in some cases. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Collegium Pharmaceutical may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
A clear view of Collegium Pharmaceutical comes from reviewing its financial structure and trends. Additional context for Collegium Pharmaceutical Stock is provided in the reports below: